Dashboard PDUFA PDUFA History Dilution Watch Missed Milestones Earnings Big Movers Blog

🎤 Upcoming Biotech Conferences

Loading conferences...

Free to browse, no account needed Track ASMB with free AI briefings, catalyst countdowns, and dilution alerts.

ASMB · Assembly Biosciences, Inc.

Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.

$320.4M Cash, Jun 2026

51mo Cash Runway (est.)

+165% Share Count, 1 Year

Follow ASMB by email Get an email when ASMB pushes back a promised milestone, files for a stock offering or has an FDA decision. Free, no account needed.

We send one confirmation email first. Only emails about ASMB, unsubscribe in one click. Privacy

📣 What ASMB Says Is Next

first quarter of 2027 · “In addition, a Phase 2 basket study in cholestatic liver diseases, focused on PBC and PSC, is expected to begin in the first quarter of 2027, subject to regulatory feedback.”
Company press release, May 22, 2026 · SEC filing
fourth quarter of 2026 · “The company plans to initiate a Phase 2 clinical study of ABI‑6250 in HDV in the fourth quarter of 2026.”
Company press release, May 22, 2026 · SEC filing
fourth quarter of 2026 · “Initiation of a Phase 2 clinical study for ABI-6250 in participants with chronic hepatitis delta virus (HDV) infection expected in the fourth quarter of 2026 Upcoming Conferences”
Company press release, May 7, 2026 · SEC filing

Quoted word for word from the company's press releases filed with the SEC. Timing is the company's own guidance, not a BioRadar estimate.

💰 Cash Runway & Dilution Risk

ASMB reported $320.4M in cash and short-term investments (as of Jun 30, 2026) and used about $18.9M/quarter in operations, an estimated runway of 50.7 months at that rate (BioRadar estimate, not company guidance).

Dilution pressure: 45 · Elevated

Cash runway 51 months
ATM program on file since Mar 2026 +15
Shelf registration (S-3, Mar 2026) +10
Share count +165% in a year +20

Recent financing filings on SEC EDGAR:

May 26, 2026 · Underwritten offering · 424B5
May 22, 2026 · Underwritten offering · 424B5
Mar 19, 2026 · Shelf registration with ATM program, up to $100M · S-3
Aug 11, 2025 · Underwritten offering · 424B5
Aug 11, 2025 · Underwritten offering · 424B5
Aug 11, 2025 · Private placement (8-K Item 3.02) · 8-K

Source: SEC EDGAR (XBRL cash flow and financing filings). Dilution Watch: every company ranked → · Get an alert when ASMB files for a raise →

Get the full ASMB picture

The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ASMB and every other ticker you follow. Card required, cancel anytime.

Start 7-day free trial →

Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z